ArriVent BioPharma, Inc.

Contributing Author

Recent Articles by ArriVent BioPharma, Inc.

Dec-22	ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer AVBP GlobeNewswire
Nov-10	ArriVent BioPharma Reports Third Quarter 2025 Financial Results AVBP GlobeNewswire
Sep-22	ArriVent Appoints Brent S. Rice as Chief Commercial Officer AVBP GlobeNewswire
Sep-09	Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer AVBP GlobeNewswire
Aug-11	ArriVent BioPharma Reports Second Quarter 2025 Financial Results AVBP GlobeNewswire
Jul-21	ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 AVBP GlobeNewswire
Jul-01	ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants AVBP GlobeNewswire
Jul-01	ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants AVBP GlobeNewswire
Jun-23	ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study AVBP GlobeNewswire
Jun-20	ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC AVBP GlobeNewswire
May-12	ArriVent BioPharma Reports First Quarter 2025 Financial Results AVBP GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.